spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Ortho Biotech 

 HSMN NewsFeed - 22 Sep 2014
Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2014
Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2012
Sirona Biochem Names Neil Belenkie as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 24 Apr 2012
Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Mar 2012
Delcath Expands Global Marketing Team With Key Pharma Oncology Hire
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 1 Feb 2012
Dendreon Announces CEO and Chairman Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2011
Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2011
Jules A. Müsing Joins iBio’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2011
Shionogi Announces New US Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 Feb 2011
Savient Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2011
Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2010
Tranzyme Pharma Appoints Pharmaceutical Industry Veteran John H. Johnson as Chairman of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2010
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Feb 2010
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2009
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 14 Sep 2009
Lilly Names New Business Leaders
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Sep 2009
FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2009
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jul 2009
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2009
Pfizer's Oncology Business Unit Appoints Vice President of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Mar 2009
Pfizer's Oncology Business Unit Appoints Senior Executive to Head U.S. Region
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Feb 2009
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Dec 2008
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2008
Amgen and Ortho Biotech Settle Antitrust Suit
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2008
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2008
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Mar 2008
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 19 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 5 Nov 2007
MedImmune Announces Seven Key Promotions and New Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 20 Sep 2007
FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
Biopharmaceuticals
 HSMN NewsFeed - 5 Sep 2007
Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
ImClone Systems Appoints John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2007
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 7 May 2007
AEterna Zentaris Bolsters Management Team with Two Key Positions Named
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2007
Somaxon Pharmaceuticals Names James L'Italien, Ph.D. Senior Vice President, Regulatory Affairs and Quality Assurance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2007
Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin alfa)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2007
Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Feb 2007
Cobalis Appoints Three Pharmaceutical Industry Executives to Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jan 2007
Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2006
Curis Announces Key Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2006
Majority of Cancer-Related Anemia Patients Treated With PROCRIT(R) (Epoetin Alfa) Once Every Three Weeks Achieved Target Hemoglobin
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2006
Majority of Anemic Chronic Kidney Disease Pre-Dialysis Patients Achieved Target Hemoglobin Range With PROCRIT(R) (Epoetin alfa) Therapy Initiated Every Two Weeks
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Study Evaluates Real-World Dosing and Cost Considerations for PROCRIT(R) (Epoetin Alfa) and Darbepoetin Alfa in the Inpatient Hospital Setting
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2006
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 5 Oct 2006
Curis, Inc. Announces Genentech Filing of Investigational New Drug Application for Systemic Administration of a Hedgehog Antagonist
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2006
Curis, Inc. Agrees to Settlement with Micromet AG
Biopharmaceuticals Litigation
 HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 12 Sep 2006
Curis, Inc. Announces New Cancer Programs, Formation of China-Based Subsidiary
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Jun 2006
In a Phase III Lipid Interim Analysis, ACAPODENE Treatment Lowered Cholesterol and Raised HDL In Prostate Cancer Patients On Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes
Biopharmaceuticals Wound Care
Return to NewsFeed  

 Additional items found! 117

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 117 additional stories matching:
Ortho Biotech
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.